Sort
130,381 grants matching “hiv”
Vectored delivery of anti-HIV antibodies for mucosal protection
$785,297Jose Maria Martinez-Navio · University Of Miami School Of Medicine · R01 · FY2023 · AI
Enhancing HIV Prevention Through a Multi-level Community Intervention To Promote
$785,289Margaret R Weeks · Institute For Community Research · R01 · FY2011 · MH
Defining the role of T cell help in germinal centers by intercellular enzymatic labeling
$785,027Gabriel D Victora · Rockefeller University · R01 · FY2022 · AI
Impact of microbiota on AIDS-Kaposiâs sarcoma development and therapy
$785,019Shou-Jiang Gao · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Relationship of fungal translocation, inflammation, and pulmonary function in HIV
$785,014Alison Morris · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HL
Relationship of fungal translocation, inflammation, and pulmonary function in HIV
$785,014Barbara Methe · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL
Intersection of Material-Need Insecurities and HIV and Cardiovascular Health
$785,001Sheri Dawn Weiser · University Of California, San Francisco · R01 · FY2023 · HL
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
$785,000Peter S Kim · Stanford University · DP1 · FY2018 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2021 · DA
Manipulating Epigenetic Control Mechanisms to Control HIV Transcription
$785,000Jonathan Karn · Case Western Reserve University · DP1 · FY2009 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2022 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2020 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2019 · DA
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
$785,000Peter S Kim · Stanford University · DP1 · FY2017 · DA
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
$785,000Peter S Kim · Stanford University · DP1 · FY2021 · DA
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
$785,000Peter S Kim · Stanford University · DP1 · FY2020 · DA
Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery
$785,000Peter S Kim · Stanford University · DP1 · FY2019 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2018 · DA
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection
$784,938Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
$784,933Susan B Zolla-Pazner · New York University School Of Medicine · P01 · FY2016 · AI
Immunopathogenesis Of Chlamydia trachomatis Infection
$784,894Thomas Quinn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Regulation of HIV latency by microglial-neuronal interactions
$784,868Jonathan Karn · Case Western Reserve University · R01 · FY2023 · DA
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTG
$784,832David Eric Shapiro · Harvard School Of Public Health · U01 · FY2009 · AI
Baylor College of Medicine Clinical Trial Unit
$784,766William Thomas Shearer · Baylor College Of Medicine · U01 · FY2010 · AI
HIV PREVENTION PROJECTS
$784,765Sharon G Renter · Wyoming State Department Of Health · U62 · FY2006 · PS